about
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cellsExome sequencing identifies recurrent somatic RAC1 mutations in melanomaIntegrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implicationsDetecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies.Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.MicroRNA signatures differentiate melanoma subtypes.Phosphoproteomic screen identifies potential therapeutic targets in melanoma.Plasma markers for identifying patients with metastatic melanoma.Integrated analysis of tumor samples sheds light on tumor heterogeneity.Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitorsExome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.GNA14 Somatic Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation.Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells.MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.Clonal growth of human melanocytes using cell-free extracellular matrix.Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer.Pre-treatment patient selection for nivolumab benefit based on serum mass spectra.A Serum Protein Signature Associated with Outcome After Anti-PD1 Therapy in Metastatic Melanoma.Early B cell changes predict autoimmunity following combination immune checkpoint blockade.Abstract LB-104: Excited electrons in melanin induce cyclobutane dimers in the darkA novel anti-melanoma SRC-family kinase inhibitor
P50
Q24606438-DAABC000-951B-4207-B7DF-92C541A26C2DQ24607661-892B5ABC-24C8-4CF4-9A2F-AD7E0E1F8C06Q28474843-1E4D3690-0A54-4E75-BA7A-D3983FAA0368Q33898708-A9EE64F5-4B2C-4973-9570-EDD280974BD4Q34049618-6CD03A49-CEA0-4824-82C6-75A55FBB0DF4Q34182764-0B5E72BA-FD62-46AB-AF55-A94917BF7183Q35053505-17B31CD1-20AA-4828-B321-014A7CE8C0BBQ36152030-E8B4A0AE-C0F8-4A57-85B8-0C269C78A5A8Q36247937-9F40C348-DDFE-42F9-BDCC-D62F9E5E0819Q36676466-8A943746-4E8B-4C8F-A32B-67F3CA870561Q37028299-33BA3BD8-B0C0-4CD1-9FE3-9C1069CE1E67Q37153016-5D071994-808A-424E-A05B-6B859319BF7BQ37509860-E354497B-724D-4EE6-A466-8DAE2F1B96F6Q37571700-AE452987-685A-4BAB-90C4-C9AC39C0A6F1Q39096305-24BEBFD4-C737-4FDB-8F2B-1756DC74C78CQ39226193-578CA5DF-7AE0-4512-878B-F8DD7CE91921Q40118823-5C5B373B-34AC-49AD-85E3-CFAAA11AB11AQ45800745-0B090358-F74F-4930-99A5-C5DCDECDE5FDQ45943266-AB5FEEF6-D4AC-4FEF-AA37-6C9B9027B30DQ50140526-9D564145-B386-4B9B-8968-A1BE76DDA227Q62660989-8EFDD0E8-8E2D-41DB-8D18-2B0E3F744E56Q64077348-6E5342AA-D952-4B0D-B8FE-71767F26A1E9
P50
name
Antonella Bacchiocchi
@ast
Antonella Bacchiocchi
@en
Antonella Bacchiocchi
@nl
type
label
Antonella Bacchiocchi
@ast
Antonella Bacchiocchi
@en
Antonella Bacchiocchi
@nl
prefLabel
Antonella Bacchiocchi
@ast
Antonella Bacchiocchi
@en
Antonella Bacchiocchi
@nl